| Name | Title | Contact Details |
|---|
Were NUU. We make unlocked Android smartphones. Weve been doing it since 2012. NUU is a global company with strong, local roots and today weve grown across the globe from Hong Kong to Dallas, TX and beyond. Our philosophy is simple — better smartphones, better prices. We believe a good-looking, reliable phone doesnt have to cost hundreds of dollars. We believe in protecting our customers with extended warranties and timely updates. We believe a friendly voice and top-notch customer service make a difference. Our beautiful smartphones feature reliable, premium-quality technology at affordable prices. And, with NUU phones, you have the freedom to select the mobile service provider thats best for you. Choose your own level of technological comfort. Do you want all the latest bells and whistles a high-tech phone has to offer? Weve got that – phones with extended batteries, fingerprint security, facial recognition technology, and more. But we also offer entry-level smartphones that get the job done – talking, texting and video calls – for a lot less than youd expect. For each member of your family, theres a NUU smartphone that fits your needs - and your budget. Were NUU, and our passion is connecting you to the world around you.
The Minnesota Twins are a professional baseball team based in Minneapolis, Minnesota. They play in the Central Division of Major League Baseballs American League. Winners of the 1987 and 1991 World Series. Stay up to date on everything about the Twins at www.twinsbaseball.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.